Literature DB >> 10668808

Prevention of venous thromboembolism.

G Agnelli1, F Sonaglia.   

Abstract

Venous thromboembolism is the most common cause of preventable death among hospitalised patients. Systematic prophylaxis with antithrombotic agents in patients at risk for venous thromboembolism is the most effective approach to reduce morbidity and mortality. Despite this evidence, antithrombotic prophylaxis is still underused, due to the underestimation of incidence of venous thromboembolism and to the unjustified fear of bleeding complications. Both the characteristics of the individual patient and the clinical setting contribute to the definition of the risk for venous thromboembolism. Patient-related risk factors include clinical and molecular abnormalities. The grade of risk for venous thromboembolism is defined better by the clinical setting than by the patient characteristics. Prophylactic studies have been extensively carried out in surgical patients and, only more recently, in medical patients. Prophylactic methods include pharmacological agents, such as heparin, low molecular weight heparins, warfarin, and hirudin, as well as mechanical methods such as compression stockings and intermittent pneumatic compression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10668808     DOI: 10.1016/s0049-3848(99)00207-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Venous thromboembolism in COPD hospitalized patients.

Authors:  Raquel Barba; Antonio Zapatero; Javier Marco; Juan E Losa; Susana Plaza; Jose Manuel Casas; Jesús Canora
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

2.  Residents case report: deep vein thrombosis in a high school baseball pitcher following ulnar collateral ligament (ucl) reconstruction.

Authors:  Joseph Hannon; Craig Garrison; John Conway
Journal:  Int J Sports Phys Ther       Date:  2013-08

Review 3.  Pentasaccharides for the prevention of venous thromboembolism.

Authors:  Kezhou Dong; Yanzhi Song; Xiaodong Li; Jie Ding; Zhiyong Gao; Daopei Lu; Yimin Zhu
Journal:  Cochrane Database Syst Rev       Date:  2016-10-31

Review 4.  Deep venous thrombosis prophylaxis in patients with heart disease.

Authors:  B K Shively
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 5.  Prevention of venous thromboembolism in spinal surgery.

Authors:  S Brambilla; C Ruosi; G A La Maida; S Caserta
Journal:  Eur Spine J       Date:  2003-11-11       Impact factor: 3.134

6.  Cutoff values of plasma d-dimer level in patients with diagnosis of the venous thromboembolism after elective spinal surgery.

Authors:  Saeed Hamidi; Mahdieh Riazi
Journal:  Asian Spine J       Date:  2015-04-15

Review 7.  Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yanzhi Song; Xiaodong Li; Settipalli Pavithra; Dong Li
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

8.  Medical rota changes and venous thromboembolism prophylaxis in orthopaedic patients.

Authors:  Iain Bohler; Alan George Mackenzie Jardine
Journal:  BMJ Qual Improv Rep       Date:  2014-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.